Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
2027. jan. 4.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
2026. dec. 31.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Primary anorectal melanoma with BRAF V600 wild-type status presenting with widespread metastases in a 29-year-old man: a case report.
2026. nov. 4.· Journal of surgical case reports· PUBMED
Publikáció
ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials.
2026. okt. 30.· Journal of gastrointestinal cancer· PUBMED
Publikáció
Targeted BRAF /MEK inhibition as a salvage therapy for patients with metastatic melanoma harboring a BRAF L597R mutation: two case reports and review of the literature.
2026. okt. 28.· Melanoma research· PUBMED
Publikáció
Treatment discontinuation after complete response to BRAF/MEK inhibition in metastatic melanoma: long-term clinical outcomes from a single institution.
2026. okt. 28.· Melanoma research· PUBMED
Publikáció
Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.
2026. okt. 28.· Annals of hematology· PUBMED
Publikáció
Beyond BRAF V600: emerging MAPK-targeted therapeutic strategies.
2026. okt. 23.· Annals of translational medicine· PUBMED
Publikáció
Multimodal treatment of isolated leptomeningeal relapse in BRAF-mutated dMMR colon cancer.
2026. okt. 23.· European journal of cancer (Oxford, England : 1990)· PUBMED
Publikáció
Cytotoxic activity of selinexor in BRAFV600E-driven pediatric low-grade glioma 3D cultures.
2026. okt. 22.· Acta neuropathologica communications· PUBMED
Publikáció
BRAF-Targeted Anticancer Agents: Synthesis, Molecular Docking, and In Vitro Evaluation of Novel 1,3,4-Thiadiazolyl-Benzamide Derivatives.
2026. okt. 22.· Current drug discovery technologies· PUBMED
Vizsgálat
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
2026. okt. 20.· NA · RECRUITING· CTGOV
Publikáció
Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma.
2026. okt. 20.· Experimental hematology & oncology· PUBMED
Publikáció
Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study.
2026. okt. 20.· Combinatorial chemistry & high throughput screening· PUBMED
Publikáció
Deep learning techniques in predicting BRAF mutation status in cutaneous melanoma from histopathologic images.
2026. okt. 18.· Journal of clinical pathology· PUBMED
Publikáció
From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma.
2026. okt. 17.· American journal of clinical dermatology· PUBMED
Publikáció
Pharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma.
2026. okt. 16.· Disease models & mechanisms· PUBMED
Publikáció
Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.
2026. okt. 16.· JCO precision oncology· PUBMED
Publikáció
[Patients with papillary craniopharyngioma successfully treated with BRAF and MEK inhibitors].
2026. okt. 16.· Lakartidningen· PUBMED
Publikáció
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.
2026. okt. 15.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Quantitative systems pharmacology modeling of class I-III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design.
2026. okt. 13.· iScience· PUBMED
Publikáció
Prevalence and Diagnostic Performance of the BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Cross-Sectional Study in Uruguay.
2026. okt. 12.· Acta cytologica· PUBMED
Publikáció
Diagnostic Accuracy of VE1 Immunohistochemistry for BRAF p.V600E in Colorectal Carcinoma: A Systematic Review.
2026. okt. 12.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up.
2026. okt. 8.· Frontiers in endocrinology· PUBMED
Publikáció
The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
2026. okt. 8.· Leukemia research reports· PUBMED
Publikáció
Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.
2026. okt. 2.· European journal of cancer (Oxford, England : 1990)· PUBMED
Publikáció
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.
2026. okt. 2.· JCO precision oncology· PUBMED
Publikáció
Correction: BRAFV600E-Driven Lung Adenocarcinoma Requires Copper to Sustain Autophagic Signaling and Processing.
2026. okt. 2.· Molecular cancer research : MCR· PUBMED
Vizsgálat
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
2026. okt. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV